Innovative
Biopharmaceutical Company

Based on MitoTransfer

Who We Are

PAEAN Biotechnology, a pioneer in mitochondria-based therapeutics, is the first company to develop mitochondria as biopharmaceutical agents to treat diseases. Using our first-in-class proprietary technology of isolating, storing, and modifying mitochondria, we developed a revolutionary treatment to address rare diseases and cancer.

Mission

PAEAN Biotechnology strives to develop revolutionary first-in-class medicinal products through a proprietary platform based on the unique characteristics of mitochondria. We have developed three platforms of MitoTransfer.

MitoTransfer Therapeutics

Read more >>

Cell Therapeutics Augmented by MitoTransfer

Read more >>

Modified MitoTransfer

Read more >>

Milestone

Seoul National University Hospital



Research Collaboration

2018 - Now

Pre-series A Funding

Korea Investment Partners



KRW 1.5 B

Jun 2018

Series A Funding

Korea Investment Partners, Hana Ventures, Timefolio


KRW 6 B

Jun 2019

Bridge Funding

Korea Investment Partners, Hana Ventures, Timefolio


KRW 4.5 B

Jan 2021

Mitochondria GMP Facility



Jung-gu, Seoul

Jun 2021

Press Highlights

파이안바이오, 미토콘드리아 치료제 국내 1·2a상 승인

국내 1-2a상 승인 Source: https://www.hankyung.com/it/article/202106179415i

Read more >>
Jun 17, 2021

120억원 투자 받은 파이안바이오, 미토콘드리아 신약 임상 계획 승인

Source: https://biz.chosun.com/stock/stock_general/2021/06/17/Y2ICBHE75RHZTN3XCFO3LXGUVE/

Read more >>
Jun 17, 2021

IND Approval for PN-101 by MFDS

PAEAN Biotechnology, a company specializing in the development of new mitochondrial drugs, announced today that the Ministry of Food and Drug Safety (MFDS) has approved the Investigational New Drug (I...

Read more >>
Jun 16, 2021